Decoy Therapeutics Inc. Income Statement
DCOY|7 years of annual SEC 10-K data (FY2016-FY2022)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 7 fiscal years. All figures from audited SEC 10-K filings.
Decoy Therapeutics Inc. reported $2M in revenue and $13M in net loss for FY2022. Revenue has grown at a 16.2% compound annual rate over the past 4 years.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -3.27 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|
| Revenue | $1.8M | $5.2M | $3.5M | $2.0M | $1.0M | $0 | $0 |
| Cost of Revenue | - | - | - | - | $662.7K | $0 | $0 |
| SG&A Expense | $6.1M | $6.1M | $7.7M | $2.3M | $19.9M | $16.5M | $4.0M |
| R&D Expense | $8.5M | $6.9M | $4.0M | $1.3M | $20.4M | $12.7M | $4.0M |
| Operating Income | -$12.8M | -$7.8M | -$8.3M | -$1.7M | -$39.9M | -$29.2M | -$8.0M |
| Income Tax | - | - | - | $0 | - | - | - |
| Net Income | -$12.8M | -$7.4M | -$6.9M | -$1.7M | -$39.5M | -$29.1M | -$8.0M |
| EPS (Basic) | -$7.72 | -$0.50 | - | - | - | - | - |
| EPS (Diluted) | -$7.72 | -$0.50 | -$2.12 | -$1.16 | -$2.43 | -$2.08 | -$4.57 |
| Shares Outstanding | 1.8M | 23.8M | 4.5M | 2.0M | 17.8M | 16.8M | 15.7M |
| Operating Margin | -696.3% | -148.8% | -238.5% | -86.3% | -3946.5% | - | - |
| Profit Margin | -693.8% | -140.5% | -200.2% | -85.6% | -3907.7% | - | - |